Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Gallwitz

Showing results (51-60 of 67) with videos related to

Pageof 7
Sort By:
Diabetologia|March 31, 2009
A common genetic variant in WFS1 determines impaired glucagon-like peptide-1-induced insulin secretionS A Schäfer, K Müssig, H Staiger, et al.
European Journal of Clinical Investigation|July 20, 1999
Comparison of the effect of native glucagon-like peptide 1 and dipeptidyl peptidase IV-resistant analogues on insulin release from rat pancreatic isletsE G Siegel, G Scharf, B Gallwitz, et al.
Diabetologia|February 1, 2006
Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humansJ J Meier, A Gethmann, O Götze, et al.
Diabetologia|May 24, 2003
Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemiaJ J Meier, B Gallwitz, N Siepmann, et al.
Diabetes, Obesity & Metabolism|April 8, 2015
Treatment escalation options for patients with type 2 diabetes after failure of exenatide twice daily or glimepiride added to metformin: results from the prospective European Exenatide (EUREXA) studyG Schernthaner, J Rosas-Guzmán, F Dotta, et al.
Diabetes, Obesity & Metabolism|November 27, 2014
Regardless of the degree of glycaemic control, linagliptin has lower hypoglycaemia risk than all doses of glimepiride, at all time points, over the course of a 2-year trialB Gallwitz, J Rosenstock, S Patel, et al.
European Journal of Biochemistry|November 1, 1994
Structure/activity characterization of glucagon-like peptide-1B Gallwitz, M Witt, G Paetzold, et al.
The Journal of Endocrinology|December 23, 1999
Insulin secretion defects in liver cirrhosis can be reversed by glucagon-like peptide-1E G Siegel, A Seidenstücker, B Gallwitz, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 15, 1991
Isolation and primary structure of pituitary human galanin, a 30-residue nonamidated neuropeptideW E Schmidt, H Kratzin, K Eckart, et al.
Diabetologia|July 13, 2005
Secretion of incretin hormones and the insulinotropic effect of gastric inhibitory polypeptide in women with a history of gestational diabetesJ J Meier, B Gallwitz, M Askenas, et al.
Pageof 7

Showing results (51-60 of 67) with videos related to

Sort By:
Pageof 7
Diabetologia|March 31, 2009
A common genetic variant in WFS1 determines impaired glucagon-like peptide-1-induced insulin secretionS A Schäfer, K Müssig, H Staiger, et al.
European Journal of Clinical Investigation|July 20, 1999
Comparison of the effect of native glucagon-like peptide 1 and dipeptidyl peptidase IV-resistant analogues on insulin release from rat pancreatic isletsE G Siegel, G Scharf, B Gallwitz, et al.
Diabetologia|February 1, 2006
Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humansJ J Meier, A Gethmann, O Götze, et al.
Diabetologia|May 24, 2003
Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemiaJ J Meier, B Gallwitz, N Siepmann, et al.
Diabetes, Obesity & Metabolism|April 8, 2015
Treatment escalation options for patients with type 2 diabetes after failure of exenatide twice daily or glimepiride added to metformin: results from the prospective European Exenatide (EUREXA) studyG Schernthaner, J Rosas-Guzmán, F Dotta, et al.
Diabetes, Obesity & Metabolism|November 27, 2014
Regardless of the degree of glycaemic control, linagliptin has lower hypoglycaemia risk than all doses of glimepiride, at all time points, over the course of a 2-year trialB Gallwitz, J Rosenstock, S Patel, et al.
European Journal of Biochemistry|November 1, 1994
Structure/activity characterization of glucagon-like peptide-1B Gallwitz, M Witt, G Paetzold, et al.
The Journal of Endocrinology|December 23, 1999
Insulin secretion defects in liver cirrhosis can be reversed by glucagon-like peptide-1E G Siegel, A Seidenstücker, B Gallwitz, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 15, 1991
Isolation and primary structure of pituitary human galanin, a 30-residue nonamidated neuropeptideW E Schmidt, H Kratzin, K Eckart, et al.
Diabetologia|July 13, 2005
Secretion of incretin hormones and the insulinotropic effect of gastric inhibitory polypeptide in women with a history of gestational diabetesJ J Meier, B Gallwitz, M Askenas, et al.
Pageof 7